Tandem Diabetes Care (TNDM) Shares Down 19.5%
Tandem Diabetes Care Inc (NASDAQ:TNDM) shares traded down 19.5% during trading on Friday . The stock traded as low as $2.14 and last traded at $2.35. 6,295,264 shares traded hands during trading, an increase of 599% from the average session volume of 900,277 shares. The stock had previously closed at $2.92.
Several research analysts have commented on the company. Zacks Investment Research downgraded Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Saturday, January 20th. Robert W. Baird reissued a “hold” rating and set a $3.00 target price on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Tandem Diabetes Care presently has a consensus rating of “Hold” and a consensus target price of $11.29.
The company has a debt-to-equity ratio of -2.70, a current ratio of 1.90 and a quick ratio of 0.88. The company has a market cap of $26.51, a P/E ratio of -0.12 and a beta of 0.44.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/tandem-diabetes-care-tndm-shares-down-19-5/1855971.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.